Cargando…

Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report

RATIONALE: Factor X (FX) deficiency is a rare autosomal recessive bleeding disorder. The majority of patients carry a missense mutation in F10, and patients with bleeding disorders are either homozygous or compound heterozygous for F10. Nonsense mutations are exceptionally rare, and a heterozygous n...

Descripción completa

Detalles Bibliográficos
Autores principales: Arita, Kotaro, Niimi, Hideki, Yamagishi, Nana, Ueno, Tomohiro, Kitajima, Isao, Sugiyama, Toshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999474/
https://www.ncbi.nlm.nih.gov/pubmed/29879041
http://dx.doi.org/10.1097/MD.0000000000010950
_version_ 1783331432595193856
author Arita, Kotaro
Niimi, Hideki
Yamagishi, Nana
Ueno, Tomohiro
Kitajima, Isao
Sugiyama, Toshiro
author_facet Arita, Kotaro
Niimi, Hideki
Yamagishi, Nana
Ueno, Tomohiro
Kitajima, Isao
Sugiyama, Toshiro
author_sort Arita, Kotaro
collection PubMed
description RATIONALE: Factor X (FX) deficiency is a rare autosomal recessive bleeding disorder. The majority of patients carry a missense mutation in F10, and patients with bleeding disorders are either homozygous or compound heterozygous for F10. Nonsense mutations are exceptionally rare, and a heterozygous nonsense mutation is not considered to cause bleeding disorders. PATIENT CONCERNS: A 35-year-old Japanese female with an incidental hemorrhage after gynecologic polypectomy was referred to our hospital. DIAGNOSES: Following differential diagnostic workup, including cross-mixing test, congenital FX deficiency was strongly suspected. INTERVENTION: Coagulation tests and mutation analyses were conducted for the patient and her parents. OUTCOMES: Mutation analysis revealed that she carried a heterozygous nonsense mutation in F10. Pedigree analysis revealed that the mutation was inherited from her mother although there was no familial history of bleeding or hemostatic disturbance. LESSONS: Hemostatic disturbance may occur even in a patient with heterozygous F10. Because heterozygous nonsense mutation in F10 is expected to be hidden in an apparently healthy population, as observed in our patient, unexpected hemostatic disturbance may occur, particularly during the use of direct oral anticoagulant (DOAC)-targeting factor Xa for thrombotic diseases. FX activity should be evaluated before prescribing DOACs to patients.
format Online
Article
Text
id pubmed-5999474
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-59994742018-06-20 Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report Arita, Kotaro Niimi, Hideki Yamagishi, Nana Ueno, Tomohiro Kitajima, Isao Sugiyama, Toshiro Medicine (Baltimore) Research Article RATIONALE: Factor X (FX) deficiency is a rare autosomal recessive bleeding disorder. The majority of patients carry a missense mutation in F10, and patients with bleeding disorders are either homozygous or compound heterozygous for F10. Nonsense mutations are exceptionally rare, and a heterozygous nonsense mutation is not considered to cause bleeding disorders. PATIENT CONCERNS: A 35-year-old Japanese female with an incidental hemorrhage after gynecologic polypectomy was referred to our hospital. DIAGNOSES: Following differential diagnostic workup, including cross-mixing test, congenital FX deficiency was strongly suspected. INTERVENTION: Coagulation tests and mutation analyses were conducted for the patient and her parents. OUTCOMES: Mutation analysis revealed that she carried a heterozygous nonsense mutation in F10. Pedigree analysis revealed that the mutation was inherited from her mother although there was no familial history of bleeding or hemostatic disturbance. LESSONS: Hemostatic disturbance may occur even in a patient with heterozygous F10. Because heterozygous nonsense mutation in F10 is expected to be hidden in an apparently healthy population, as observed in our patient, unexpected hemostatic disturbance may occur, particularly during the use of direct oral anticoagulant (DOAC)-targeting factor Xa for thrombotic diseases. FX activity should be evaluated before prescribing DOACs to patients. Wolters Kluwer Health 2018-06-18 /pmc/articles/PMC5999474/ /pubmed/29879041 http://dx.doi.org/10.1097/MD.0000000000010950 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Arita, Kotaro
Niimi, Hideki
Yamagishi, Nana
Ueno, Tomohiro
Kitajima, Isao
Sugiyama, Toshiro
Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report
title Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report
title_full Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report
title_fullStr Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report
title_full_unstemmed Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report
title_short Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report
title_sort factor x heterozygous mutation in a patient with potential risk of bleeding: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999474/
https://www.ncbi.nlm.nih.gov/pubmed/29879041
http://dx.doi.org/10.1097/MD.0000000000010950
work_keys_str_mv AT aritakotaro factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport
AT niimihideki factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport
AT yamagishinana factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport
AT uenotomohiro factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport
AT kitajimaisao factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport
AT sugiyamatoshiro factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport